Louise Chantelot, Emilie Sitterlé, S. Poirée, Vincent Jullien, François Danion, Alexandra Serris
Cerebral aspergillosis is a well-recognized and particularly severe manifestation of invasive aspergillosis, primarily affecting immunocompromised individuals. The condition is associated with high morbidity and mortality, largely due to diagnostic challenges and limited treatment options. This review examines the epidemiology, risk factors, and diagnostic issues before focusing on drug treatment, including the pharmacokinetics and pharmacodynamics of antifungal agents in the central nervous system. Resistance to current antifungal therapies is also discussed, along with future research directions.